HORMAD1 and lung cancer: To further investigate whether HORMAD1 promotes EMT and metastatic behaviors in lung cancer cells via the Wnt/β-catenin pathway, we treated H157-HORMAD1 and H650-HORMAD1 KO cells with the Wnt/β-catenin signaling specific inhibitor XAV939 or activator CHIR99021, respectively.